BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Mobius Theraputics™ Receives Investment From BioGenerator


2/4/2011 8:28:55 AM

ST. LOUIS, MO--(Marketwire - February 04, 2011) - Mobius Therapeutics™, LLC, a St. Louis-based ophthalmic company and developers of Mitosol today announced the company has been awarded an investment from St. Louis-based life sciences organization, BioGenerator. The investment will be used by Mobius Therapeutics to hire additional employees to execute the commercial launch of the product. The funding also ensures Mobius Therapeutics will remain in St. Louis.

"I am pleased that BioGenerator sees the value of Mobius Therapeutics and our unique glaucoma treatment system," said Ed Timm, President of Mobius Therapeutics. "This investment from BioGenerator will help us positively impact the lives of hundreds of thousands of glaucoma patients for years to come."

BioGenerator is privately-funded organization that has been supported historically through contributions from organizations such as the McDonnell Foundation, Danforth Foundation and the Monsanto Fund. They conducted a thorough due diligence review of Mobius Therapeutics before awarding the investment. BioGenerator has recently invested in other St. Louis companies including Akermin, Cardialen, Pulse Therapeutics, Nawgan and Galera.

"We identified Mobius Therapeutics as an emerging business with a solid plan, not only to help glaucoma patients, but to contribute to and grow our local economy," said Dan Broderick of BioGenerator. "We are proud to help a growing, St. Louis-based small business who is clearly focused on creating jobs and improving patient outcomes."

About Mobius Therapeutics, LLC:
Mobius Therapeutics is an early stage venture focused on ophthalmic surgery solutions. Its first product, Mitosol, is a system for delivering antifibrotic agents in glaucoma, refractive, and corneal surgery. It is awaiting regulatory approval, with additional product applications in earlier stages of development.

About BioGenerator:
BioGenerator is a privately funded, non-profit organization created to facilitate the formation of life science companies in the St. Louis area. Founded in 2003, BioGenerator's mission is to support economic development for the St. Louis region, to identify promising life science technology, and to build successful, sustainable life science companies.


CONTACT:
Jim Anderson
Mobius Therapeutics, LLC
+1 314-615-6930
Email Contact

Andy Likes
The Vandiver Group, Inc.
+1 314-991-4641
Email Contact



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->